Target Selection Strategy Lab: What Makes a Winning Radiopharmaceutical Target?
1:30 pm - Tuesday 1st December 2026
- Evaluating the biological, translational and clinical characteristics that separate promising radiopharmaceutical targets from those unlikely to succeed in development
- Debating how developers should balance target expression, tumour selectivity, internalisation, accessibility and heterogeneity when prioritising targets for investment
- Comparing the opportunities and limitations of established and emerging targets including DLL3, FAP, CAIX and others to determine where the next wave of radiopharmaceutical innovation will emerge